Yüklüyor......
PHASE I TRIAL OF MOTEXAFIN GADOLINIUM AND DOXORUBICIN IN THE TREATMENT OF ADVANCED MALIGNANCIES
PURPOSE: To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors. STUDY DESIGN: The combination of MGd and doxorubicin was administered every 28 days (cycle 1)...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2009
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3038176/ https://ncbi.nlm.nih.gov/pubmed/19997959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-009-9364-z |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|